Organogenesis Executive and Leadership Team

Gary Gillheeney, the President, Chief Executive Officer and Chair of the Board at Organogenesis, directs the company's overarching strategy and governance. Gillheeney oversees all executive functions, ensuring alignment with the mission of empowering healing through regenerative medicine. This leadership position involves guiding the organization's expansion within the advanced wound care, surgical, and sports medicine sectors. The Chair of the Board role requires strategic oversight of corporate direction and stakeholder relations. Gary Gillheeney drives the company's vision, focusing on sustainable growth and market impact. The Chief Executive Officer's responsibilities include fostering innovation and ensuring operational excellence across all departments. This executive's mandate encompasses long-term financial health and market positioning. The President's purview extends to all aspects of business operations and strategic partnerships. Gillheeney's tenure is marked by a commitment to advancing patient care through cutting-edge regenerative therapies.

Philip Laughlin, the Chief Executive Officer & President & Board Member at Organogenesis, executes the company's strategic initiatives and operational management. Laughlin's role involves driving growth and innovation in regenerative medicine, specifically within advanced wound care and surgical markets. The President's responsibilities include overseeing daily operations and ensuring efficient resource allocation. As Chief Executive Officer, Philip Laughlin guides the company's long-term vision and market penetration strategies. This board member position ensures robust corporate governance and strategic alignment with shareholder interests. Laughlin's leadership focuses on enhancing product development pipelines and expanding market reach. The Chief Executive Officer & President & Board Member ensures seamless integration of research, manufacturing, and commercialization efforts. Philip Laughlin's impact is evident in the company's commitment to empowering healing and improving patient outcomes. This executive's strategic direction supports Organogenesis's mission across its key market segments.

David Francisco, the Chief Financial Officer at Organogenesis, directs the company's financial planning, reporting, and capital allocation strategies. Francisco oversees all fiscal operations, ensuring financial stability and supporting the company's growth objectives in regenerative medicine. The Chief Financial Officer's responsibilities include managing investor relations and securing funding for research and development initiatives. David Francisco's strategic financial guidance is critical for Organogenesis's expansion in the advanced wound care and surgical markets. This executive's role involves rigorous financial analysis and risk management to support long-term sustainability. The Chief Financial Officer ensures compliance with all financial regulations and reporting requirements. David Francisco's expertise is vital for optimizing resource utilization and driving profitability. This leadership position underpins the company's ability to empower healing through sound financial management.

Patrick Bilbo, the Chief Operating Officer at Organogenesis, manages the company's manufacturing, supply chain, and operational efficiency. Bilbo oversees the production of advanced wound care and surgical products, ensuring adherence to stringent quality standards. The Chief Operating Officer's responsibilities include optimizing production processes and driving operational excellence across all facilities. Patrick Bilbo directs the supply chain management, ensuring timely delivery of critical regenerative medicine solutions to the market. This executive's focus is on scaling operations to meet growing demand and maintaining cost-effectiveness. The Chief Operating Officer plays a key role in implementing new manufacturing technologies and improving workflow. Patrick Bilbo's leadership ensures the reliable and efficient production of Organogenesis's innovative therapies. This role is fundamental to the company's ability to empower healing through consistent product availability.

Michael Catarina, the Chief Technology Officer at Organogenesis, architects the company's technological advancements and innovation pipeline. Catarina leads the research and development efforts, focusing on novel regenerative medicine solutions for advanced wound care and surgical applications. The Chief Technology Officer's mandate includes overseeing the integration of cutting-edge scientific discoveries into manufacturable products. Michael Catarina drives the technological strategy, ensuring Organogenesis remains at the forefront of the regenerative medicine market. This role involves managing intellectual property and fostering a culture of scientific excellence. The Chief Technology Officer's responsibilities extend to ensuring the scalability and robustness of the company's product platforms. Michael Catarina's expertise is critical in developing next-generation therapies that empower healing. This executive's vision shapes the future of Organogenesis's product portfolio and technological infrastructure.

Michael Sabolinski, the Chief Marketing Officer at Organogenesis, spearheads the company's market penetration and brand development strategies. Sabolinski directs all commercial activities, focusing on expanding Organogenesis's presence in the advanced wound care, surgical, and sports medicine markets. The Chief Marketing Officer's responsibilities include identifying new market opportunities and driving revenue growth through targeted campaigns. Michael Sabolinski oversees product positioning and go-to-market strategies, ensuring alignment with the company's mission to empower healing. This executive's leadership is crucial for communicating the value proposition of Organogenesis's regenerative medicine solutions. The Chief Marketing Officer manages customer engagement and builds strong relationships with healthcare providers. Michael Sabolinski's strategic insights inform product development and market expansion initiatives. This role is pivotal in establishing Organogenesis as a leader in regenerative therapies.